Advances in Clinical and Experimental Medicine

Title abbreviation: Adv Clin Exp Med
JCR Impact Factor (IF) – 2.1
5-Year Impact Factor – 2.2
Scopus CiteScore – 3.4 (CiteScore Tracker 3.7)
Index Copernicus  – 161.11; MNiSW – 70 pts

ISSN 1899–5276 (print)
ISSN 2451-2680 (online)
Periodicity – monthly

Download original text (EN)

Advances in Clinical and Experimental Medicine

2018, vol. 27, nr 1, January, p. 125–133

doi: 10.17219/acem/65691

Publication type: review

Language: English

Download citation:

  • BIBTEX (JabRef, Mendeley)
  • RIS (Papers, Reference Manager, RefWorks, Zotero)

Genetic polymorphisms and their involvement in the regulation of the inflammatory response in asthma and COPD

Juan M. Reséndiz-Hernández1,2,A,B,C,D, Ramcés Falfán-Valencia1,A,B,C,D,E,F

1 HLA Laboratory, National Institute of Respiratory Diseases Ismael Cosio Villegas, Mexico City, Mexico

2 Graduate Program in Biological Sciences, National Autonomous University of Mexico, Mexico City, Mexico

Abstract

Asthma and chronic obstructive pulmonary disease (COPD) are widely documented diseases with an inflammatory component. Asthma is a heterogeneous disorder of the airways that involves chronic inflammation, decline of the airway function and tissue remodeling. Chronic obstructive pulmonary disease is a preventable and treatable disease, which is characterized by persistent limited airflow, and is usually progressive with an increased inflammatory response in the airways. The inflammatory response is evoked by the stimulus of noxious particles and gases. Inflammation is a natural process in response to injury, but in asthma and COPD patients it occurs as an abnormal immune response to pathogenic stimuli which induce chronic inflammation, a key process in the pathogenesis of both diseases. However, the inflammatory process is different in both diseases, and is involved in several release patterns of inflammation mediators. It is not entirely clear whether these proteins are simply markers of the inflammatory process that accompanies a chronic disease or if they play a major role in the pathogenesis of the disease. The main proteins which have been described in these illnesses are: IL-4, IL-6, IL-8, and TNF-α. In addition, polymorphisms have been described in genes encoding these proteins that alter the transcription and susceptibility associated with these diseases. In this review, we will focus on asthma and COPD, and the involvement of these proteins and their genetic polymorphisms.

Key words

asthma, COPD, gene regulation, SNP, TNF-α

References (117)

  1. Holgate ST, Polosa R. Treatment strategies for allergy and asthma. Nat Rev Immunol. 2008;8(3):218–230.
  2. Kallal LE, Lukacs NW. The role of chemokines in virus-associated asthma exacerbations. Curr Allergy Asthma Rep. 2008;8(5):443–450.
  3. Leong AB, Ramsey CD, Celedón JC. The challenge of asthma in minority populations. Clin Rev Allergy Immunol. 2012;43(1–2):156–183. doi:10.1007/s12016–011–8263–1.
  4. Nelson HS. The importance of allergens in the development of asthma and the persistence of symptoms. Dis Mon. 2001;47(1):5–15.
  5. Karjalainen J, Hulkkonen J, Nieminen MM, et al. Interleukin-10 gene promoter region polymorphism is associated with eosinophil count and circulating immunoglobulin E in adult asthma. Clin Exp Allergy. 2003;33(1):78–83.
  6. Holgate ST, Davies DE, Powell RM, Howarth PH, Haitchi HM, Holloway JW. Local genetic and environmental factors in asthma disease pathogenesis: Chronicity and persistence mechanisms. Eur Respir J. 2007;29(4):793–803.
  7. Holgate ST. Pathogenesis of asthma. Clin Exp Allergy. 2008;38(6):872–897.
  8. Kearley J, Robinson DS, Lloyd CM. CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol. 2008;122(3):617–624.
  9. Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;30;326(5):298–304.
  10. Foster PS, Martinez-Moczygemba M, Huston DP, Corry DB. Interleukins-4, -5, and -13: Emerging therapeutic targets in allergic disease. Pharmacol Ther. 2002;94(3):253–264.
  11. Hamelmann E, Cieslewicz G, Schwarze J, et al. Anti-interleukin 5 but not anti-IgE prevents airway inflammation and airway hyperresponsiveness. Am J Respir Crit Care Med. 1999;160(3):934–941.
  12. Kumar RK, Herbert C, Yang M, Koskinen AM, McKenzie AN, Foster PS. Role of interleukin-13 in eosinophil accumulation and airway remodelling in a mouse model of chronic asthma. Clin Exp Allergy. 2002;32(7):1104–1111.
  13. Louten J, Boniface K, de Waal Malefyt R. Development and function of TH17 cells in health and disease. J Allergy Clin Immunol. 2009;123(5):1004–1111.
  14. Grünig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science. 1998;282(5397):2261–2263.
  15. Shim JJ, Dabbagh K, Ueki IF, et al. IL-13 induces mucin production by stimulating epidermal growth factor receptors and by activating neutrophils. Am J Physiol Lung Cell Mol Physiol. 2001;280(1):134–140.
  16. Sidhu SS, Yuan S, Innes AL, et al. Roles of epithelial cell-derived periostin in TGF-beta activation, collagen production, and collagen gel elasticity in asthma. Proc Natl Acad Sci U S A. 2010;107(32):14170–14175.
  17. Takayama G, Arima K, Kanaji T, et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol. 2006;118(1):98–104.
  18. Williams CM, Galli SJ. Mast cells can amplify airway reactivity and features of chronic inflammation in an asthma model in mice. J Exp Med. 2000;192(3):455–462.
  19. Yu M, Tsai M, Tam SY, Jones C, Zehnder J, Galli SJ. Mast cells can promote the development of multiple features of chronic asthma in mice. J Clin Invest. 2006;116(6):1633–1641.
  20. Balzar S, Fajt ML, Comhair SA, et al. Mast cell phenotype, location, and activation in severe asthma. Data from the Severe Asthma Research Program. Am J Respir Crit Care Med. 2011;183(3):299–309.
  21. Van Beijsterveldt CE, Boomsma DI. Genetics of parentally reported asthma, eczema and rhinitis in 5-yr-old twins. Eur Respir J. 2007;29(3):516–521.
  22. Sleiman PM, Flory J, Imielinski M, et al. Variants of DENND1B associated with asthma in children. N Engl J Med. 2010;7;362(1):36–44.
  23. Li X, Howard TD, Zheng SL, et al. Genome-wide association study of asthma identifies RAD50-IL13 and HLA-DR/DQ regions. J Allergy Clin Immunol. 2010;125(2):328–335.
  24. Torgerson DG, Ampleford EJ, Chiu GY, et al. Meta-analysis of genome-wide association studies of asthma in ethnically diverse North American populations. Nat Genet. 2011;43(9):887–892. doi:10.1038/ng.888.
  25. Hoffjan S, Nicolae D, Ober C. Association studies for asthma and atopic diseases: A comprehensive review of the literature. Respir Res. 2003;4:14.
  26. Bals R, Hiemstra PS. Innate immunity in the lung: Now epithelial cells fight against respiratory pathogens. Eur Respir J. 2004;(2):327–333.
  27. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD); 2014. Available from http://goldcopd.org/. Accessed June 5, 2015.
  28. Donaldson GC, Seemungal TA, Patel IS, et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005;128(4):1995–2004.
  29. Garrod R, Marshall J, Barley E, Fredericks S, Hagan G. The relationship between inflammatory markers and disability in chronic obstructive pulmonary disease (COPD). Prim Care Respir J. 2007;16(4):236–240.
  30. Menezes AM, Lopez MV, Hallal PC, et al. Prevalence of smoking and incidence of initiation in the Latin American adult population: The PLATINO study. BMC Public Health. 2009;9:151.
  31. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med. 2004;24;350(26):2645–2653.
  32. Hogg JC, Senior RM. Chronic obstructive pulmonary disease – Part 2: Pathology and biochemistry of emphysema. Thorax. 2002;57(9):830–834.
  33. Panina-Bordignon P, D’Ambrosio D. Chemokines and their receptors in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2003;9:104–110.
  34. Saetta M, Mariani M, Panina-Bordignon P, et al. Increased expression of the chemokine receptor CXCR3 and its ligand CXCL10 in peripheral airways of smokers with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;165:1404–1409.
  35. Morrison D, Strieter RM, Donnelly SC, Burdick MD, Kunkel SL, MacNee W. Neutrophil chemokines in bronchoalveolar lavage fluid and leukocyte-conditioned medium from nonsmokers and smokers. Eur Respir J. 1998;12:1067–1072.
  36. Kuschner WG, D’Alessandro A, Wong H, Blanc PD. Dose-dependent cigarette smoking-related inflammatory responses in healthy adults. Eur Respir J. 1996;9:1989–1994.
  37. Keatings VM, Collins PD, Scott DM, Barnes PJ. Differences in interleukin-8 and tumor necrosis factor-a in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med. 1996;153:530–534.
  38. Yamamoto C, Yoneda T, Yoshikawa M, et al. Airway inflammation in COPD assessed by sputum levels of interleukin-8. Chest. 1997;112:505–510.
  39. Woolhouse IS, Bayley DL, Stockley RA. Sputum chemotactic activity in chronic obstructive pulmonary disease: Effect of alpha(l)-antitrypsin deficiency and the role of leukotriene B(4) and interleukin 8. Thorax. 2002;57:709–714.
  40. Wilson AG, Symons JA, McDowell TL, McDevitt HO, Duff GW. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A. 1997;94:3195–3199.
  41. Huang SL, Su CH, Chang SC. Tumor necrosis factor-alpha gene polymorphism in chronic bronchitis. Am J Respir Crit Care Med. 1997;156:1436–1439.
  42. Argilés JM, López-Soriano J, Busquets S, López-Soriano FJ. Journey from cachexia to obesity by TNF. FASEB J. 1997;11:743–751.
  43. Takabatake N, Sata M, Inoue S, et al. A novel polymorphism in secretory phospholipase A2-IID is associated with body weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172:1097–1104.
  44. Hull J, Thomson A, Kwiatkowski D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax. 2000;55:1023–1027.
  45. Heinzmann A, Ahlert I, Kurz T, Berner R, Deichmann KA. Association study suggests opposite effects of polymorphisms within IL8 on bronchial asthma and respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2004;114:671–676.
  46. Shen L, Fahey JV, Hussey SB, Asin SN, Wira CR, Fanger MW. Synergy between IL-8 and GM-CSF in reproductive tract epithelial cell secretions promotes enhanced neutrophil chemotaxis. Cell Immunol. 2004;230:23–32.
  47. Beyer K, Nickel R, Freidhoff L, et al. Association and linkage of atopic dermatitis with chromosome 13q12–14 and 5q31–33 markers. J Invest Dermatol. 2000;115(5):906–908.
  48. Kroegel C, Bakakos P. The inflammatory effector cell pattern in asthma and chronic obstructive pulmonary disease – What is it good for? Respiration. 2012;83(1):17–19.
  49. Yokoyama A, Kohno N, Sakai K, Kondo K, Hirasawa Y, Hiwada K. Circulating levels of soluble interleukin-6 receptor in patients with bronchial asthma. Am J Respir Crit Care Med. 1997;156(5):1688–1691.
  50. Tillie-Leblond I, Pugin J, Marquette CH, et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. Am J Respir Crit Care Med. 1999;159(2):487–494.
  51. Neveu WA, Allard JL, Raymond DM, et al. Elevation of IL-6 in the allergic asthmatic airway is independent of inflammation but associates with loss of central airway function. Respir Res. 2010;8:11–28.
  52. Bhowmik A, Seemungal TA, Sapsford RJ, Wedzicha JA. Relation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbations. Thorax. 2000;55(2):114–120.
  53. Song W, Zhao J, Li Z. lnterleukin-6 in bronchoalveolar lavage fluid from patients with COPD. Chin Med J. 2001;114:1140–1142.
  54. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med. 2003;97:1299–1302.
  55. Wedzicha JA, Seemungal TA, MacCallum PK, et al. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost. 2000;84:210–215.
  56. Debigare R, Marquis K, Cote CH, et al. Catabolic-anabolic balance and muscle wasting in patients with COPD. Chest. 2003;124:83–89.
  57. Hull J, Ackerman H, Isles K, et al. Unusual haplotypic structure of IL8, a susceptibility locus for a common respiratory virus. Am J Hum Genet. 2001; 69(2):413–419.
  58. Damiá Ade D, Gimeno JC, Ferrer MJ, Fabregas ML, Folch PA, Paya JM. A study of the effect of proinflammatory cytokines on the epithelial cells of smokers, with or without COPD. Arch Bronconeumol. 2011;47(9):447–453.
  59. Patel KK, Vicencio AG, Du Z, Tsirilakis K, Salva PS, Webley WC. Infectious Chlamydia pneumoniae is associated with elevated interleukin-8 and airway neutrophilia in children with refractory asthma. Pediatr Infect Dis J. 2010;29(12):1093–1098.
  60. Mukhopadhyay S, Hoidal JR, Mukherjee TK. Role of TNF-alpha in pulmonary pathophysiology. Respir Res. 2006;11:7–125.
  61. Jardim MJ, Dailey L, Silbajoris R, Diaz-Sanchez D. Distinct microRNA expression in human airway cells of asthmatic donors identifies a novel asthma-associated gene. Am J Respir Cell Mol Biol. 2012;47(4):536–542. doi:10.1165/rcmb.2011–0160OC.
  62. Waserman S, Nair P, Snider D, et al. Local and systemic immunological parameters associated with remission of asthma symptoms in children. Allergy Asthma Clin Immunol. 2012;8(1):16. [Epub ahead of print]
  63. Tanni SE, Pelegrino NR, Angeleli AY, Correa C, Godoy I. Smoking status and tumor necrosis factor-alpha mediated systemic inflammation in COPD patients. J Inflamm. 2010;7:29.
  64. Chen YC, Liu SF, Chin CH, et al. Association of tumor necrosis factor-alpha-863C/A gene polymorphism with chronic obstructive pulmonary disease. Lung. 2010;188(4):339–347.
  65. Messer G, Spengler U, Jung MC, Honold G, Blömer K, Pape GR. Polymorphic structure of the tumor necrosis factor (TNF) locus: An NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF-beta production. J Exp Med. 1991;1:173(1):209–219.
  66. Migita O, Noguchi E, Koga M, et al. Haplotype analysis of a 100 kb region spanning TNF-LTA identifies a polymorphism in the LTA promoter region that is associated with atopic asthma susceptibility in Japan. Clin Exp Allergy. 2005;35(6):790–796.
  67. Tomasdottir H, Hjartarson H, Ricksten A, Wasslavik C, Bengtsson A, Ricksten SE. Tumor necrosis factor gene polymorphism is associated with enhanced systemic inflammatory response and increased cardiopulmonary morbidity after cardiac surgery. Anesth Analg. 2003;97(4):944–949.
  68. Paul WE. Interleukin-4: A prototypic immunoregulatory lymphokine. Blood. 1991;1;77(9):1859–1870.
  69. Paul WE. Interleukin 4: Signalling mechanisms and control of T cell differentiation. Ciba Found Symp. 1997;204:208–219.
  70. Swain SL, Weinberg AD, English M, Huston G. IL-4 directs the development of Th2-like helper effectors. J Immunol. 1990;1;145(11):3796–3806.
  71. Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifactorial diseases: Gateways to novel targets for immunotherapy? Trends Pharmacol Sci. 2003;24(6):284–289.
  72. Merghani TH, Saeed A, Alawad A. Changes in plasma IL4, TNF-a and CRP in response to regular passive smoking at home among healthy school children in Khartoum. Sudan. Afr Health Sci. 2012;12(1): 41–47.
  73. Li-Weber M, Krafft H, Krammer PH. A novel enhancer element in the human IL-4 promoter is suppressed by a position-independent silencer. J Immunol. 1993;151(3):1371–1382.
  74. Li-Weber M, Salgame P, Hu C, Krammer PH. Characterization of constitutive and inducible transcription factors binding to the P2 NF-AT site in the human interleukin-4 promoter. Gene. 1997;188(2):253–260.
  75. Schols AM, Buurman WA, Staal van den Brekel AJ, Dentener MA, Wouters EF. Evidence for a relation between metabolic derangements and increased levels of inflammatory mediators in a subgroup of patients with chronic obstructive pulmonary disease. Thorax. 1996;51(8):819–824.
  76. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, et al. C reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006;27(5):902–907.
  77. Weissenbach J, Chernajovsky Y, Zeevi M, et al. Two interferon mRNAs in human fibroblasts: In vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A. 1980;77(12):7152–7156.
  78. Yoshizaki K, Nakagawa T, Kaieda T, Muraguchi A, Yamamura Y, Kishimoto T. Induction of proliferation and Ig production in human B leukemic cells by anti-immunoglobulins and T cell factors. J Immunol. 1982;128(3):1296–1301.
  79. Okada M, Sakaguchi N, Yoshimura N, et al. B cell growth factors and B cell differentiation factor from human T hybridomas. Two distinct kinds of B cell growth factor and their synergism in B cell proliferation. J Exp Med. 1983;157(2):583–590.
  80. Hirano T, Taga T, Nakano N, et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci U S A. 1985;82(16):5490–5494.
  81. Van Damme J, Opdenakker G, Simpson RJ, et al. Identification of the human 26-kD protein, interferon beta 2 (IFN-beta 2), as a B cell hybridoma/plasmacytoma growth factor induced by interleukin 1 and tumor necrosis factor. J Exp Med. 1987;165(3):914–919.
  82. Galicia JC, Tai H, Komatsu Y, Shimada Y, Akazawa K, Yoshie H. Polymorphisms in the IL-6 receptor (IL-6R) gene: Strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 2004;5(6):513–516.
  83. Hawkins GA, Robinson MB, Hastie AT, et al. The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol. 2012;130(2):510–515. doi:10.1016/j.jaci.2012.03.018
  84. He JQ, Foreman MG, Shumansky K, et al. Associations of IL6 polymorphisms with lung function decline and COPD. Thorax. 2009;64(8):698–704.
  85. Yanbaeva DG, Dentener MA, Spruit MA, et al. IL6 and CRP haplotypes are associated with COPD risk and systemic inflammation: A case-control study. BMC Med Genet. 2009;10:23.
  86. Yasukawa K, Hirano T, Watanabe Y, et al. Structure and expression of human B cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J. 1987;6(10):2939–2945.
  87. Sehgal PB, Zilberstein A, Ruggieri RM, et al. Human chromosome 7 carries the beta 2 interferon gene. Proc Natl Acad Sci U S A. 1986;83(14):5219–5222.
  88. Walther Z, May LT, Sehgal PB. Transcriptional regulation of the interferon-beta 2/B cell differentiation factor BSF-2/hepatocyte-stimulating factor gene in human fibroblasts by other cytokines. J Immunol. 1988;140(3):974–977.
  89. Ray A, Sassone-Corsi P, Sehgal PB. A multiple cytokine- and second messenger-responsive element in the enhancer of the human interleukin-6 gene: Similarities with c-fos gene regulation. Mol Cell Biol. 1989;9(12):5537–5547.
  90. Poli V, Mancini FP, Cortese R. IL-6DBP, a nuclear protein involved in interleukin-6 signal transduction, defines a new family of leucine zipper proteins related to C/EBP. Cell. 1990;63(3):643–653.
  91. Aihara M, Tsuchimoto D, Takizawa H, et al. Mechanisms involved in Helicobacter pylori-induced interleukin-8 production by a gastric cancer cell line, MKN45. Infect Immun. 1997;65(8):3218–3224.
  92. Khabar KS, Al-Zoghaibi F, Al-Ahdal MN, et al. The alpha chemokine, interleukin 8, inhibits the antiviral action of interferon alpha. J Exp Med. 1997;186(7):1077–1085.
  93. Mukaida N, Shiroo M, Matsushima K. Genomic structure of the human monocyte-derived neutrophil chemotactic factor IL-8. J Immunol. 1989;143(4):1366–1371.
  94. Remick DG, Villarete L. Regulation of cytokine gene expression by reactive oxygen and reactive nitrogen intermediates. J Leukoc Biol. 1996;59(4):471–475.
  95. Shaw G, Kamen R. Pillars article: A conserved AU sequence from the 3’ untranslated region of GM-CSF mRNA mediates selective mRNA degradation. Cell. 1986;46:659–667. J Immunol. 2012;189(1):5–13.
  96. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J. 2003;22(4):672–688.
  97. Wouters EF, Reynaert NL, Dentener MA, Vernooy JH. Systemic and local inflammation in asthma and chronic obstructive pulmonary disease: Is there a connection? Proc Am Thorac Soc. 2009;6(8):638–647.
  98. Pennica D, Nedwin GE, Hayflick JS, et al. Human tumour necrosis factor: Precursor structure, expression and homology to lymphotoxin. Nature. 1984;312(5996):724–729.
  99. Gray PW, Aggarwal BB, Benton CV, et al. Cloning and expression of cDNA for human lymphotoxin, a lymphokine with tumour necrosis activity. Nature. 1984;312(5996):721–724.
  100. Hajeer AH, Dababneh A, Makki RF, et al. Different gene loci within the HLA-DR and TNF regions are independently associated with susceptibility and severity in Spanish rheumatoid arthritis patients. Tissue Antigens. 2000;55(4):319–325.
  101. Nedwin GE, Naylor SL, Sakaguchi AY, et al. Human lymphotoxin and tumor necrosis factor genes: Structure, homology and chromosomal localization. Nucleic Acids Res. 1985;13(17):6361–6373.
  102. Caput D, Beutler B, Hartog K, Thayer R, Brown-Shimer S, Cerami A. Identification of a common nucleotide sequence in the 3’-untranslated region of mRNA molecules specifying inflammatory mediators. Proc Natl Acad Sci U S A. 1986;83(6):1670–1674.
  103. Beutler B. Application of transcriptional and posttranscriptional reporter constructs to the analysis of tumor necrosis factor gene regulation. Am J Med Sci. 1992;303(2):129–133.
  104. Kruys V, Beutler B, Huez G. Translational control mediated by UA-rich sequences. Enzyme. 1990;44(1–4):193–202.
  105. Fiers W, Beyaert R, Boone E, et al. TNF-induced intracellular signaling leading to gene induction or to cytotoxicity by necrosis or by apoptosis. J Inflamm. 1996;47(1–2):67–75.
  106. Wong GH, Goeddel DV. Induction of manganous superoxide dismutase by tumor necrosis factor: Possible protective mechanism. Science. 1988;242(4880):941–944.
  107. Opipari AW Jr, Hu HM, Yabkowitz R, Dixit VM. The A20 zinc finger protein protects cells from tumor necrosis factor cytotoxicity. J Biol Chem. 1992;267(18):12424–12427.
  108. Jäättelä M, Wissing D. Heat-shock proteins protect cells from monocyte cytotoxicity: Possible mechanism of self-protection. J Exp Med. 1993;177(1):231–236.
  109. Kroeger KM, Carville KS, Abraham LJ. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol. 1997;34(5):391–399.
  110. Schulz S, Schagdarsurengin U, Suss T, Müller-Werdan U, Werdan K, Gläser C. Relation between the tumor necrosis factor-alpha (TNF-alpha) gene and protein expression, and clinical, biochemical, and genetic markers: Age, body mass index and uric acid are independent predictors for an elevated TNF-alpha plasma level in a complex risk model. Eur Cytokine Netw. 2004;15(2):105–111.
  111. Udalova IA, Richardson A, Denys A, et al. Functional consequences of a polymorphism affecting NF-kappaB p50-p50 binding to the TNF promoter region. Mol Cell Biol. 2000;20(24):9113–9119.
  112. Yannopoulos A, Nikiteas N, Chatzitheofylaktou A, Tsigris C. The (-590 C/T) polymorphism in the interleukin-4 gene is associated with increased risk for early stages of corolectal adenocarcinoma. In Vivo. 2007;21(6):1031–1035.
  113. Choi EH, Lee HJ, Yoo T, Chanock SJ. A common haplotype of interleukin-4 gene IL4 is associated with severe respiratory syncytial virus disease in Korean children. J Infect Dis. 2002;186(9):1207–1211.
  114. Quirico-Santos T, Suppiah V, Heggarty S, Caetano R, Alves-Leon S, Vandenbroeck K. Study of polymorphisms in the interleukin-4 and IL-4 receptor genes in a population of Brazilian patients with multiple sclerosis. Arq Neuropsiquiatr. 2007;65(1):15–19.
  115. Pereira DS, Garcia DM, Narciso FM, et al. Effects of 174 G/C polymorphism in the promoter region of the interleukin-6 gene on plasma IL-6 levels and muscle strength in elderly women. Braz J Med Biol Res. 2011;44(2):123–129.
  116. Gordon A, Kiss-Toth E, Stockley I, Eastell R, Wilkinson JM. Polymorphisms in the interleukin-1 receptor antagonist and interleukin-6 genes affect risk of osteolysis in patients with total hip arthroplasty. Arthritis Rheum. 2008;58(10):3157–3165.
  117. Lee WP, Tai DI, Lan KH, Li AF, Hsu HC, Lin EJ. The -251T allele of the interleukin-8 promoter is associated with increased risk of gastric carcinoma featuring diffuse-type histopathology in Chinese population. Clin Cancer Res. 2005;11(18):6431–6441.
© Wroclaw Medical University